Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jul 2022 Results from NCT02940262; NCT03353740, NCT03396874, retrospectively evaluating disease extent in men stratified by EAU BCR risk groups or biochemical persistence ,presented at the 37th Congress of the European Association of Urology
06 Oct 2020 Status changed from active, no longer recruiting to completed.
15 Feb 2020 Results, assessing the impact of 68Ga-PSMA-11 PET/CT on management of biochemically recurrent prostate cancer in a large prospective cohort, presented at the 2020 Genitourinary Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com